By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Actavis 

Morris Corporate Center III
400 Interpace Parkway
Parippany  New Jersey  07054  U.S.A.
Phone: 1-862-261-7000 Fax: n/a


SEARCH JOBS

Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland.

Actavis is the world’s third-largest generics prescription drug manufacturer, with more than 750 products marketed globally through operations in more than 60 countries. Actavis’ global branded pharmaceutical business develops and markets products principally in Urology and Women’s Health, and is committed to developing and marketing biosimilars products in Women’s Health, Oncology and other therapeutic categories. In addition, Actavis is the fourth-largest U.S. generic pharmaceutical product distributor through its Anda, Inc. business, and also develops and out-licenses generic pharmaceutical products outside of the U.S. through its Medis third-party business.

"Twice As" Video

"Our Winning Way" Video


Key Statistics


Email: actavis@actavis.com
Ownership: Public

Web Site: Actavis
Employees:
Symbol: ACT
 



Industry
Pharmaceutical






Company News
Actavis (ACT) Announces Closing Of Public Offerings Of Ordinary Shares And Mandatory Convertible Preferred Shares In Connection With Pending Acquisition Of Allergan (AGN) 3/3/2015 6:44:43 AM
Actavis (ACT) Receives Approval From The European Commission For XYDALBA (dalbavancin) 3/2/2015 7:37:08 AM
Actavis (ACT) Announces Proposed Public Offering Of Senior Notes In Connection With Pending Acquisition Of Allergan (AGN) 3/2/2015 6:47:15 AM
Actavis (ACT) Hormonal Contraceptive Device Wins FDA Approval 3/2/2015 6:36:10 AM
Actavis (ACT) And Medicines360 Announce FDA Approval Of LILETTA (Levonorgestrel-Releasing Intrauterine System) 52 Mg To Prevent Pregnancy For Up To Three Years 2/27/2015 6:46:23 AM
Actavis (ACT) Receives U.S. FDA Approval For AVYCAZ (CEFTAZIDIME-AVIBACTAM) 2/26/2015 6:48:51 AM
Actavis (ACT) Confirms Generic Uceris Patent Challenge 2/25/2015 7:15:03 AM
Actavis (ACT) Announces Pricing Of Public Offerings Of Ordinary Shares And Mandatory Convertible Preferred Shares In Connection With Pending Acquisition Of Allergan (AGN) 2/25/2015 6:53:14 AM
Actavis (ACT) Receives Final Approval For Generic Version Of Subutex 2/20/2015 10:41:14 AM
Actavis (ACT) Not Done, Still Eyes "Couple Billion Dollar" Deals to Fill Pipeline 2/19/2015 6:50:10 AM
12345678910...
//-->